Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Akebia Therapeutics (AKBA) Invested Capital (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed Invested Capital for 10 consecutive years, with $80.9 million as the latest value for Q4 2025.

  • Quarterly Invested Capital rose 870.68% to $80.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $80.9 million through Dec 2025, up 870.68% year-over-year, with the annual reading at $80.9 million for FY2025, 870.68% up from the prior year.
  • Invested Capital for Q4 2025 was $80.9 million at Akebia Therapeutics, down from $89.2 million in the prior quarter.
  • The five-year high for Invested Capital was $213.9 million in Q1 2021, with the low at -$31.4 million in Q3 2023.
  • Average Invested Capital over 5 years is $69.9 million, with a median of $72.8 million recorded in 2022.
  • The sharpest move saw Invested Capital plummeted 355.96% in 2024, then surged 2362.49% in 2025.
  • Over 5 years, Invested Capital stood at $171.6 million in 2021, then tumbled by 58.43% to $71.3 million in 2022, then tumbled by 94.25% to $4.1 million in 2023, then plummeted by 355.96% to -$10.5 million in 2024, then soared by 870.68% to $80.9 million in 2025.
  • According to Business Quant data, Invested Capital over the past three periods came in at $80.9 million, $89.2 million, and $76.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.